VRDN Overview

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Wall Street analysts forecast VRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRDN is41.71 USD with a low forecast of 14.20 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Viridian Therapeutics Inc revenue for the last quarter amounts to 132.00K USD, increased 83.33

Viridian Therapeutics Inc. EPS for the last quarter amounts to -1.27 USD, increased 28.28

Viridian Therapeutics Inc (VRDN) has 252 emplpoyees as of March 12 2026.

Today VRDN has the market capitalization of 2.90B USD.